Tracking the Market Landscape of Companies Striving to Derive Actionable Insights from the Data Deluge Through the Incorporation of Artificial Intelligence
Biomarker Analytics has always been one of the most in-demand branches of science relevant to the process of drug discovery and development in the Pharmaceutical Industry. Over the years several advances have been made in the area of biomarker analytics with the aim to accelerate the drug development process. The use of AI-based technology can increase the efficiency of biomarker analytics.
With the huge data deluges generated through various platforms such as omics, diagnostics etc., machine learning and deep learning techniques are slowly proving to be highly effective in sifting through data and identifying critical biomarkers through pattern recognition.
This global research service provides extensive information about industry trends, market landscape, latest technological advances and AI-based developments in the biomarker analytics industry that hold immense potential in accelerating the process of drug development in the pharmaceutical industry.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atomwise
- Benevolent AI
- Berg Health
- BioXcel Therapeutics
- ExScientia
- GNS Healthcare
- Insilico Medicine
- NuMedii
- Numerate
- Recursion Pharmaceuticals
- Standigm
- twoXAR
